Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study.
Megestrol acetate (160 mg/day) produced a response rate of 44% in a retrospective series of 39 evaluable patients with advanced breast cancer. The estrogen-receptor (ER) level was greater than 10 fmols/mg of protein in 28 patients, and the progesterone-receptor (PR) level was greater than 10 fmols/mg of protein in 26 patients. ER and PR levels, age, and disease-free interval were analyzed for their relationship to response. The PR was the single best predictor of response to megestrol acetate; the addition of ER added 2% to the predictive accuracy rate of PR alone.
D001943:Breast Neoplasms / Q000032:analysis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008535:Megestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D019290:Megestrol Acetate; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis*; D012189:Retrospective Studies
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D008535:Megestrol; D019290:Megestrol Acetate